Natural Health Trends Corp. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This filing reports annual results; standalone fourth-quarter figures are not provided in the supplied filing text.
Business context
Natural Health Trends sells NHT Global wellness, personal care and lifestyle products through direct selling and e-commerce. Its business depends on independent members and is highly concentrated in Hong Kong: 79.4% of 2023 net sales were recorded there, and substantially all Hong Kong sales were products delivered to members in China. Active members fell 16% to 32,410 at year-end.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales | $43.9 million | $49.1 million |
| Gross profit / margin | $32.7 million / 74.6% | $36.5 million / 74.2% |
| Operating income (loss) / margin | ($1.7) million / (3.8%) | ($0.3) million / (0.6%) |
| Net income / diluted EPS | $0.6 million / $0.05 | $0.3 million / $0.03 |
| Operating cash flow | ($4.3) million | ($4.9) million |
- Sales declined 11%. Hong Kong sales fell 9%; management cited tepid consumer sentiment in China, a 3% decrease in order volume, lower administrative fee revenue, and a year-over-year deferred-revenue timing difference. Sales outside Hong Kong declined 16% overall.
- Gross margin edged up, primarily reflecting lower logistics costs. Commissions were 41.9% of sales versus 42.2%. SG&A remained about $16.0 million, but rose to 36.5% of sales from 32.6% as revenue declined.
- The operating loss widened, while net income increased because other income rose to $2.4 million from $0.9 million, primarily from interest earned on cash equivalents. The income tax provision was $0.2 million, down from $0.3 million.
- Cash and cash equivalents were $56.2 million at year-end, down $13.5 million. Current assets were $64.2 million and current liabilities $20.0 million; working capital was $44.2 million and the current ratio 3.21. Cash equivalents included $47.2 million of available-for-sale investments.
- Operating cash use improved by $0.6 million year over year. Management said it improved by $2.0 million excluding income-tax payments related to repatriation of deferred foreign income ($3.0 million in 2023; $1.6 million in 2022). Dividends paid were $9.2 million, exceeding annual net income.
- The balance sheet reports no borrowings; lease liabilities totaled $3.5 million. Income taxes payable included $9.0 million related to the U.S. repatriation tax, of which $5.1 million was noncurrent. The filing identifies $3.7 million of cash held in China subject to foreign currency controls.
Material changes, outlook and risks
- Active members declined from 38,660 to 32,410, contributing to lower sales. The company remains dependent on China-related demand and faces Chinese regulatory scrutiny; it does not hold a China direct-selling license and cannot predict whether or when one may be obtained.
- COVID-related restrictions eased and the company held in-person member events in China, Macau and Hong Kong during 2023. Management plans more events but says the durability and business impact of normalized conditions remain uncertain.
- The company expects to continue a quarterly dividend of $0.20 per share for the foreseeable future, subject to Board discretion and financial conditions. A $0.20 dividend was declared in February 2024. The repurchase authorization had $21.9 million remaining at year-end.
- Management believes existing liquidity and operating cash flows should fund normal operations and commitments for the foreseeable future, while warning that continued negative operating cash flow or a substantial decline in cash could impair operations, dividends and financing capacity. No quantitative revenue or earnings guidance is provided.
- Other key risks include geographic and product concentration; reliance on third-party manufacturers, including single suppliers for several significant products; member attrition; direct-selling and product-claim regulation; foreign-exchange, trade and geopolitical risks; and cybersecurity and data-privacy exposure. The company reported no legal proceedings. It noted that it lacks comprehensive product-liability insurance.
- The auditor issued an unqualified opinion on the financial statements and reported no critical audit matters. Management concluded internal control over financial reporting was effective; the auditor was not engaged to audit those controls.
Important facts for investors to verify
- Whether sales, order volume and active-member trends stabilize, particularly in Hong Kong and China.
- How much of reported sales and future cash generation depends on deferred revenue, administrative fees and China-delivered Hong Kong orders.
- Whether negative operating cash flow persists and whether the dividend remains supportable alongside cash taxes and other commitments.
- The status and potential financial and operational consequences of Chinese regulatory reviews, business-model compliance and any future direct-selling license application.
- Supplier continuity and revenue exposure to Premium Noni Juice, Triotein and probiotic products sourced from single suppliers.
- Cash availability given foreign currency controls, the repatriation-tax liability and the company’s substantial dividend and repurchase authorizations.